Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 07/06/26
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool • 07/06/26
Lilly, This IPO Leader Among Stocks To Watch In A Mischievous MarketInvestors Business Daily • 07/06/26
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?The Motley Fool • 07/04/26
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 07/02/26
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 CoverageZacks Investment Research • 07/01/26
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?Zacks Investment Research • 06/30/26
Medicare will start covering obesity drugs for the first time. Here's what patients should knowCNBC • 06/30/26
Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 YearsThe Motley Fool • 06/30/26
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drugReuters • 06/30/26
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland ChinaPRNewsWire • 06/30/26
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reportsReuters • 06/29/26
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilitiesCNBC • 06/29/26